STUGERON Tablet (2018)
Βιβλιογραφική αναφορά
Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή
Περιεχόμενα
Name of the medicinal product
Stugeron 15 mg tablets.
Qualitative and quantitative composition
Each tablet contains 15 mg cinnarizine. Excipients with known effect: Each tablet contains 160 mg lactose monohydrate and 15 mg sucrose. For the full list of excipients, see section 6.1.
Pharmaceutical form
White circular tablet with S/15 on one side and JANSSEN on the other side.
Therapeutic indications
Stugeron is for the control of vestibular disorders such as vertigo, tinnitus, nausea and vomiting such as is seen in Menieres Disease. Stugeron is also effective in the control of motion sickness.
Posology and method of administration
Method of administration Oral. The tablets may be chewed, sucked or swallowed whole. Posology Stugeron should preferably be taken after meals. Vestibular symptoms Adults, elderly and children over 12 years: ...
Contraindications
Stugeron should not be given to patients with known hypersensitivity to cinnarizine.
Special warnings and precautions for use
As with other antihistamines, Stugeron may cause epigastric discomfort; taking it after meals may diminish the gastric irritation. In patients with Parkinsons Disease, Stugeron should only be given if ...
Interaction with other medicinal products and other forms of interaction
Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of either these drugs or of Stugeron.
Pregnancy and lactation
The safety of Stugeron in human pregnancy has not been established although studies in animals have not demonstrated teratogenic effects. As with other drugs it is not advisable to administer Stugeron ...
Effects on ability to drive and use machines
Stugeron may cause drowsiness, especially at the start of treatment; patients affected in this way should not drive or operate machinery.
Undesirable effects
The safety of Stugeron was evaluated in 372 cinnarizine-treated subjects who participated in 7 placebo-controlled trials for the indications peripheral circulatory disorders, cerebral circulatory disorders, ...
Overdose
Symptoms The signs and symptoms are mainly due to the anticholinergic (atropine-like) activity of cinnarizine. Acute cinnarizine overdoses have been reported with doses ranging from 90 to 2,250 mg. The ...
Pharmacodynamic properties
ATC Code: N07CA02 Cinnarizine has been shown to be a non-competitive antagonist of the smooth muscle contractions caused by various vasoactive agents including histamine. Cinnarizine also acts on vascular ...
Pharmacokinetic properties
In animals, cinnarizine is extensively metabolised, N-dealkylation being the major pathway. Approximately two thirds of the metabolites are excreted with the faeces, the rest in the urine, mainly during ...
Preclinical safety data
Nonclinical safety studies showed that effects were observed only after chronic exposures from approximately 7 to 35 times the recommended maximum daily human dose of 90 mg/day calculated on a body surface ...
List of excipients
Lactose monohydrate Maize starch Sucrose Talc Magnesium stearate Polyvidone K90
Incompatibilities
None known.
Shelf life
3 years.
Special precautions for storage
This medicinal product does not require any special storage conditions.
Nature and contents of container
PVC/Aluminium foil blisters or Polystyrene tubs with polyethylene caps Each pack containing 15, 25, 100, 250 or 1000 tablets. Not all pack sizes may be marketed.
Special precautions for disposal and other handling
No special requirements.
Marketing authorization holder
Janssen-Cilag Limited, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, UK
Marketing authorization number(s)
PL 00242/5009R
Date of first authorization / renewal of the authorization
Date of first authorisation: 14 September 1989 Date of latest renewal: 21 August 2001
Date of revision of the text
30 May 2018
Πηγαίο έγγραφο
Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:
